SPIRIT TECH COLLECTIVE

Compass Pathways elected Kathleen Tregoning to its Board of Directors at the annual general meeting of shareholders, announced May 28, 2026. Tregoning most recently served as Chief Corporate Affairs Officer and Head of Commercial Strategy at Cerevel Therapeutics, guiding the company through its acquisition by AbbVie in 2024. Previously she was EVP of External Affairs at Sanofi and held health policy roles in the U.S. Congress. She holds a B.A. from Stanford and an M.A. from Harvard Kennedy School. The biopharma commercialization profile signals Compass is staffing its board for commercial launch of COMP360 psilocybin therapy.

At the APA Annual Meeting in San Francisco (May 16-20, 2026), Compass Pathways CEO George Goodwin framed COMP360 psilocybin-assisted therapy as neither mushrooms nor psychotherapy but a distinct technology-enabled therapeutic modality. The dispatch from Psychedelic Alpha (published June 2) captured an institutional inflection point: mainstream American psychiatry actively grappling with how to integrate psilocybin-assisted therapy. Goodwin's positioning validates Spirit Tech's sector thesis that technology platforms — not raw compounds — define the commercial opportunity. Builds on ART0182 (Week 22, COMP360 suicidal ideation study).

Compass Pathways announced Q1 2026 financial results on May 13, reporting $466.0 million in cash and cash equivalents as of March 31, 2026, providing runway into 2028. The FDA granted NDA rolling submission and review for COMP360 psilocybin therapy for treatment-resistant depression, based on the strength of positive Phase 3 data. Sections of the NDA have already been submitted, with final submission targeted for Q4 2026. COMP360 also received a Commissioner's National Priority Voucher (CNPV), which could accelerate review to 1-2 months. 26-week Part B durability data from COMP006 expected in early Q3 2026.